Trial intelligence / Profile preview

Tipranavir/ritonavir in treatment-experienced HIV patients with hepatitis B or C coinfection

2005-005023-33Phase 3Completed

Sponsor
Boehringer Ingelheim
Start
Jan 2007
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, open-label, single-arm trial of tipranavir and ritonavir in Human immunodeficiency virus infection type 1, sponsored by Boehringer Ingelheim. Primary endpoint: Treatment response at Week 48. Started Jan 2007; status: completed.

02

Drugs

tipranavirritonavir
03

Conditions

Human immunodeficiency virus infection type 1

Beyond the preview

Go deeper on 2005-005023-33.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2005-005023-33.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call